Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NuVasive, Inc.
  6. News
  7. Summary
    NUVA   US6707041058

NUVASIVE, INC.

(NUVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NuVasive Announces First Commercial Cases Utilizing the Pulse Platform

09/30/2021 | 07:00am EST

NuVasive, Inc. announced Drs. Michael Kachmann and Zachary Tempel from Mayfield Brain & Spine in Ohio, and Dr. Paul Holman from Houston Methodist Hospital in Texas, completed the first commercial cases with the NuVasive Pulse® platform. Drs. Kachmann and Tempel successfully performed the first commercial case using Pulse in an XLIF® procedure with minimally invasive fixation and nerve root decompression at TriHealth'sGood Samaritan Hospital in Ohio, and have since leveraged Pulse in a variety of spine procedures. When treating his patient and reflecting on Pulse's surgical workflow with a less invasive procedure. Dr. Holman, a thought leader in spine navigation technology, had this to share after utilizing the Pulse platform. In addition, other leading surgeons and hospitals have selected Pulse as the technology platform for their respective spine operating rooms.


ę S&P Capital IQ 2021
All news about NUVASIVE, INC.
11/18NuVasive to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
PR
11/15Globus Medical in Talks About Possible NuVasive Takeover
MT
11/15Globus Medical Reportedly Eyes Acquisition of NuVasive
CI
11/15NuVasive Shares Halted, Globus Reportedly Makes Early Takeover Approach
MT
11/10Morgan Stanley Adjusts NuVasive's Price Target to $62 From $67, Maintains Equalweight R..
MT
11/10UBS Adjusts NuVasive PT to $54 From $59, Maintains Sell Rating
MT
11/10Needham Cuts NuVasive's Price Target to $64 From $73, Citing Q3 Miss; Buy Rating Kept
MT
11/09Credit Suisse 30th Annual Healthcare Conference
PU
11/09NuVasive Announces Third Quarter 2021 Financial Results - Form 8-K
PU
11/09NUVASIVE INC Management's Discussion and Analysis of Financial Condition and Results o..
AQ
More news
Analyst Recommendations on NUVASIVE, INC.
More recommendations
Financials (USD)
Sales 2021 1 136 M - -
Net income 2021 -15,5 M - -
Net Debt 2021 655 M - -
P/E ratio 2021 -157x
Yield 2021 -
Capitalization 2 486 M 2 486 M -
EV / Sales 2021 2,76x
EV / Sales 2022 2,48x
Nbr of Employees 2 700
Free-Float 88,0%
Chart NUVASIVE, INC.
Duration : Period :
NuVasive, Inc. Technical Analysis Chart | NUVA | US6707041058 | MarketScreener
Technical analysis trends NUVASIVE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 48,06 $
Average target price 66,60 $
Spread / Average Target 38,6%
EPS Revisions
Managers and Directors
J. Christopher Barry Chief Executive Officer & Director
Matthew K. Harbaugh Chief Financial Officer & Executive Vice President
Daniel J. Wolterman Chairman
Kyle Malone VP-Clinical, Medical & Regulatory Affairs
Aviva McPherron Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NUVASIVE, INC.-12.64%2 546
ABBOTT LABORATORIES14.87%226 394
MEDTRONIC PLC-8.91%148 311
BECTON, DICKINSON AND COMPANY-5.23%69 191
HOYA CORPORATION26.28%58 287
DEXCOM, INC.52.17%55 343